#United States #New York #Parkinson's Disease #Michael J. Fox Foundation #JAX-NYSCF

Advancing Parkinson’s Disease Research: A Major Grant for The Jackson Laboratory

In a significant boost for Parkinson's disease research, The Jackson Laboratory (JAX) has announced that it will receive a grant of $1.8 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This funding aims to address a crucial void in the research community: the lack of standardized, scalable human cell model systems essential for exploring the complexities of Parkinson's disease biology and for facilitating therapeutic discovery efforts.

The Collaboration and Its Goals

The initiative will be undertaken through the JAX-NYSCF Collaborative, a partnership that harnesses the complementary strengths of JAX and the New York Stem Cell Foundation (NYSCF). The primary objective of this collaboration is to advance human disease modeling to expedite biomedical discoveries relating to Parkinson's disease.

One of the pivotal genetic factors in Parkinson’s disease is GBA1, which encodes an enzyme responsible for the degradation of specific lipids in the cell's recycling system. Mutations in the GBA1 gene have been linked to a higher risk of developing Parkinson’s disease, with affected individuals often experiencing earlier symptoms and more aggressive disease progression. However, much about how GBA1 mutations impair cellular function and contribute to the disease remains unclear.

Bridging the Research Gap

Nicole Polinski, MJFF's director of research resources, emphasized that one of the foundation's primary goals is to foster the creation of scalable and replicable research tools, models, and services that advance the comprehension of Parkinson's disease biology across the scientific community. By focusing on GBA1, this collaborative effort seeks to standardize and characterize accessible human cell models, which can provide insights into disease mechanisms and facilitate the assessment of potential therapies.

Stefan Semrau, co-director of the JAX-NYSCF Collaborative and principal investigator of the project, stated, "While numerous genetic variants related to Parkinson's disease have been identified, we still lack a thorough understanding of their functional roles and contributions to disease risk. Our aim is to establish standardized human cell model systems that directly link genetic alterations to cellular outcomes. These models will empower researchers and industry partners to develop innovative methodologies for studying Parkinson’s disease and testing new therapeutic options."

Research Methodology

The research team will utilize induced pluripotent stem cells (iPSCs) to develop standardized human brain cell models featuring GBA1 variants. This process includes validated approaches to study the functional characteristics of the GBA1 gene within cell environments. Researchers will aim to convert these stem cells into specific types of cells potentially associated with Parkinson's disease—particularly microglia, the brain's immune cells that may exhibit both protective and detrimental functions, and a unique class of neurons that are preferentially lost as the disease advances.

By employing advanced biochemical analyses and microscopy techniques on these models, the research team intends to uncover how impaired GBA1 functionality impacts the cellular recycling system. The expected outcomes include innovative research methods, new model systems, and comprehensive datasets that could significantly enhance the scientific community's understanding of the mechanisms behind Parkinson’s disease, ultimately facilitating more effective evaluations of potential treatments.

Synergistic Impact of the Collaborative

The JAX-NYSCF Collaborative is uniquely positioned to tackle the challenges of Parkinson’s disease research. By integrating JAX's expertise in genetics and genomics with NYSCF's cutting-edge stem cell and automation technologies, the partnership can develop human disease models that are not only biologically relevant but also standardized, scalable, and broadly beneficial to the Parkinson’s research community.

Furthermore, this research will take place in conjunction with the Early Drug Discovery Unit (EDDU) at McGill University's Montreal Neurological Institute, which will validate the models and assays to ensure reproducibility across different research environments. This multi-institutional approach ensures that the research findings can be trusted and utilized effectively across the scientific community.

About The Jackson Laboratory

Founded in 1929, the Jackson Laboratory is an independent, non-profit biomedical research institution situated in Bar Harbor, Maine. It is recognized as a National Cancer Institute-designated Cancer Center. The laboratory is dedicated to leveraging its extensive research expertise, educational initiatives, and resources to uncover precise genomic solutions for various diseases, contributing to the global scientific effort to improve human health. With nearly 3,000 employees and multiple campuses across the United States and Japan, the Jackson Laboratory is committed to advancing human health through innovative research practices. For further details, visit www.jax.org.